{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-046121","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.985879+00:00","generated_at":"2026-05-22T04:31:32.934612+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera Q1 revenue $501.8M (+36.5% YoY); positive cash flow $23.2M","bullets":["Total revenue $501.8M (+36.5% YoY); product revenue $500.0M (+37.1%).","Gross margin 63.1% (up from 56.7%); tests processed 855,100 (+16.2%).","Net loss $66.9M ($0.50 EPS) improved from $67.6M ($0.56) in prior year.","Positive operating cash flow $23.2M; cash & investments $991.6M.","Oncology test volume 167,700 (+46.1% YoY); CEO cites record Signatera growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-046121","json":"https://secwatch.observer/filing/0001104659-25-046121.json","markdown":"https://secwatch.observer/filing/0001104659-25-046121.md","text":"https://secwatch.observer/filing/0001104659-25-046121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925046121/0001104659-25-046121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925046121/tm2513945d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:31:32.934612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}